InvestorsHub Logo
Followers 6
Posts 1142
Boards Moderated 0
Alias Born 08/24/2012

Re: ziploc_1 post# 19583

Tuesday, 10/29/2013 9:26:44 PM

Tuesday, October 29, 2013 9:26:44 PM

Post# of 427141
Or will a successful Reduce-It serve as cover for all the other drugs? Everyone wants Reduce-It completed including the recent Adcomm panelists. Lovaza is still selling well, Niaspan is still recommended in the medical literature. One of this board's fears was all these new meds in the pipeline. Vascepa will be the only choice out there even if its label might not change.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News